The National Institute of Standards and Technology Genome Editing Consortium addresses the measurements and standards needed to increase confidence and lower the risk of utilizing genome editing technologies in research and commercial products. This consortium is currently active. Please see below for more detailed information on current activities.
MEMBER BENEFITS
BECOME A MEMBER
Notice of NIST’s Genome Editing Consortium Establishment
Notice of NIST’s Genome Editing Consortium Extension
PAST EVENTS
2016 NIST Genome Editing Standards Workshop: Agenda, Workshop Report
Targeted genome editing, a method used to alter the DNA of living cells at desired locations, is poised to revolutionize science and medicine. To fight diseases, novel genome edited therapeutics, including those for use in regenerative medicine and infectious diseases, are being developed. Many commercial applications including agriculture and chemical production, are also leveraging this technology. Whether genome editing will be used in healthcare, agriculture or basic research, robust quantitative measurements are needed to enable high confidence characterization of DNA alterations. NIST has brought together experts across the genome editing field including stakeholders in industry, academia and government to assess their measurement needs. These discussions have identified common pre-competitive measurements and standards needed to establish greater confidence in the characterization of genome editing outputs. The NIST-led Genome Editing Consortium has been established to address these needs.
Three working groups with the following responsibilities:
Working Group 1: Specificity Measurements
Working Group 2: Data and Metadata